Multiplex quantitation of 270 plasma protein markers to identify a signature for early detection of colorectal cancer

2020 ◽  
Vol 127 ◽  
pp. 30-40
Author(s):  
Megha Bhardwaj ◽  
Korbinian Weigl ◽  
Kaja Tikk ◽  
Tim Holland-Letz ◽  
Petra Schrotz-King ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Early Detection ◽  
Plasma Protein ◽  
Protein Markers

scholarly journals The Metabolic Syndrome, Inflammation, and Colorectal Cancer Risk: An Evaluation of Large Panels of Plasma Protein Markers Using Repeated, Prediagnostic Samples

2017 ◽  
Vol 2017 ◽  
pp. 1-9 ◽  
Author(s):  
Sophia Harlid ◽  
Robin Myte ◽  
Bethany Van Guelpen
Keyword(s):  
Colorectal Cancer ◽  
Metabolic Syndrome ◽  
Plasma Protein ◽  
Overweight And Obesity ◽  
Low Grade ◽  
Protein Markers ◽  
Intervention Programme ◽  
Large Panels ◽  
Protein Levels ◽  
The Metabolic Syndrome

Metabolic syndrome (MetS), a set of metabolic risk factors including obesity, dysglycemia, and dyslipidemia, is associated with increased colorectal cancer (CRC) risk. A putative biological mechanism is chronic, low-grade inflammation, both a feature of MetS and a CRC risk factor. However, excess body fat also induces a proinflammatory state and increases CRC risk. In order to explore the relationship between MetS, body size, inflammation, and CRC, we studied large panels of inflammatory and cancer biomarkers. We included 138 participants from the Västerbotten Intervention Programme with repeated sampling occasions, 10 years apart. Plasma samples were analyzed for 178 protein markers by proximity extension assay. To identify associations between plasma protein levels and MetS components, linear mixed models were fitted for each protein. Twelve proteins were associated with at least one MetS component, six of which were associated with MetS score. MetS alone was not related to any protein. Instead, BMI displayed by far the strongest associations with the biomarkers. One of the 12 MetS score-related proteins (FGF-21), also associated with BMI, was associated with an increased CRC risk (OR 1.71, 95% CI 1.19–2.47). We conclude that overweight and obesity, acting through both inflammation and other mechanisms, likely explain the MetS-CRC connection.

Head-to-Head Comparison and Evaluation of 92 Plasma Protein Biomarkers for Early Detection of Colorectal Cancer in a True Screening Setting

2015 ◽  
Vol 21 (14) ◽  
pp. 3318-3326 ◽  
Author(s):  
Hongda Chen ◽  
Manuela Zucknick ◽  
Simone Werner ◽  
Phillip Knebel ◽  
Hermann Brenner
Keyword(s):  
Colorectal Cancer ◽  
Early Detection ◽  
Plasma Protein ◽  
Protein Biomarkers

scholarly journals Multiplex screening of 275 plasma protein biomarkers to identify a signature for early detection of colorectal cancer

2019 ◽  
Vol 14 (1) ◽  
pp. 8-21 ◽  
Author(s):  
Megha Bhardwaj ◽  
Korbinian Weigl ◽  
Kaja Tikk ◽  
Axel Benner ◽  
Petra Schrotz‐King ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Early Detection ◽  
Plasma Protein ◽  
Protein Biomarkers

Detector-C: A Blood-based IVD with High Sensitivity and Specificity for Early Detection and Screening of Colorectal Cancer

2010 ◽  
Vol 48 (08) ◽  
Author(s):  
A Rosenthal ◽  
H Köppen ◽  
R Musikowski ◽  
R Schwanitz ◽  
J Behrendt ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Early Detection ◽  
Sensitivity And Specificity ◽  
High Sensitivity

Biomarkers for Early Detection of Colitis-associated Colorectal Cancer - Current Concepts, Future Trends

2020 ◽  
Vol 22 (1) ◽  
pp. 137-145
Author(s):  
Tomasz Mackiewicz ◽  
Aleksander Sowa ◽  
Jakub Fichna
Keyword(s):  
Colorectal Cancer ◽  
Early Detection ◽  
Cancer Development ◽  
Sporadic Colorectal Cancer ◽  
Future Trends ◽  
Significant Progress ◽  
Current Standard ◽  
Risk Of Cancer ◽  
Histological Testing ◽  
Made In

: Colitis-associated colorectal cancer (CAC) remains a critical complication of ulcerative colitis (UC) with mortality of approximately 15%, which makes early CAC diagnosis crucial. The current standard of surveillance, with repetitive colonoscopies and histological testing of biopsied mucosa samples is burdensome and expensive, and therefore less invasive methods and reliable biomarkers are needed. Significant progress has been made thanks to continuous extensive research in this field, however no clinically relevant biomarker has been established so far. This review of the current literature presents the genetic and molecular differences between CAC and sporadic colorectal cancer and covers progress made in the early detection of CAC carcinogenesis. It focuses on biomarkers under development, which can be easily tested in samples of body fluids or breath and, once made clinically available, will help to differentiate between progressors (UC patients who will develop dysplasia) from non-progressors and enable early intervention to decrease the risk of cancer development.

scholarly journals Plasma Protein Biomarkers Associated with Higher Ovarian Cancer Risk in BRCA1/2 Carriers

Cancers ◽  
2021 ◽  
Vol 13 (10) ◽  
pp. 2300
Author(s):  
Hee-Sung Ahn ◽  
Jung Yoon Ho ◽  
Jiyoung Yu ◽  
Jeonghun Yeom ◽  
Sanha Lee ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Plasma Protein ◽  
Normal Subjects ◽  
Genetic Alterations ◽  
Enzyme Linked Immunosorbent Assay ◽  
Ovarian Cancer Risk ◽  
Protein Markers ◽  
Protein Biomarkers ◽  
Proteomics Approach ◽  
Risk Reducing

Ovarian cancer (OC) is the most lethal gynecologic malignancy and in-time diagnosis is limited because of the absence of effective biomarkers. Germline BRCA1/2 genetic alterations are risk factors for hereditary OC; risk-reducing salpingo-oophorectomy (RRSO) is pursued for disease prevention. However, not all healthy carriers develop the disease. Therefore, identifying predictive markers in the BRCA1/2 carrier population could help improve the identification of candidates for preventive RRSO. In this study, plasma samples from 20 OC patients (10 patients with BRCA1/2 wild type (wt) and 10 with the BRCA1/2 variant (var)) and 20 normal subjects (10 subjects with BRCA1/2wt and 10 with BRCA1/2var) were analyzed for potential biomarkers of hereditary OC. We applied a bottom-up proteomics approach, using nano-flow LC-MS to analyze depleted plasma proteome quantitatively, and potential plasma protein markers specific to the BRCA1/2 variant were identified from a comparative statistical analysis of the four groups. We obtained 1505 protein candidates from the 40 subjects, and SPARC and THBS1 were verified by enzyme-linked immunosorbent assay. Plasma SPARC and THBS1 concentrations in healthy BRCA1/2 carriers were found to be lower than in OC patients with BRCA1/2var. If plasma SPARC concentrations increase over 337.35 ng/ml or plasma THBS1 concentrations increase over 65.28 mg/ml in a healthy BRCA1/2 carrier, oophorectomy may be suggested.

Sign in / Sign up

Export Citation Format

Share Document